Welcome and Introductions
Vince Anzalone, CFA
Vice President, Investor Relations
Safe Harbor Statement

This presentation contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including, without limitation, our developmental stage and limited operating history, our ability to successfully and timely develop products, enter into collaborations and obtain projected milestone payments and licensing fees, our ability to fund our operations, rapid technological change in our markets, demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K, recent and forthcoming Quarterly Reports on Form 10-Q, recent Current Reports on Forms 8-K, and other SEC filings discuss some of the important risk factors that may affect our ability to achieve the anticipated results, as well as our business, results of operations and financial condition. Readers are cautioned not to place undue reliance on these forward-looking statements. Additionally, Arrowhead disclaims any intent to update these forward-looking statements to reflect subsequent developments.
Panelists

New York University Langone School of Medicine

**Ira Goldberg, M.D.**
Bronfman Professor of Medicine
Chief of the Division of Endocrinology, Diabetes and Metabolism

Arrowhead Pharmaceuticals

**Vince Anzalone, CFA**
Vice President, Investor Relations

**Chris Anzalone, Ph.D.**
President and CEO

**Bruce Given, M.D.**
COO and Head of R&D

**Zhen Li, Ph.D.,**
Senior Vice President, Chemistry and Non-Clinical Development

**Erik Bush, Ph.D.,**
Senior Director, Extra-Hepatic Targeting

**So Wong, Ph.D.,**
Director, Oncology

Investor and Analyst R&D Day 2018
Agenda

• Welcome and Intros – Vince Anzalone
• Pipeline and Platform Strategy – Chris Anzalone
• Apolipoprotein C-III – Ira Goldberg
• ARO-APOC3 – Bruce Given
• Angiopoietin-like protein 3 – Ira Goldberg
• ARO-ANG3 – Bruce Given
• TRiM™ Platform – Zhen Li
• ARO-ENaC Gen1 – Erik Bush
• ARO-HIF2 – So Wong
• Concluding Remarks – Chris Anzalone
• Q & A – Panel
Pipeline and Platform Strategy
Chris Anzalone, Ph.D.
President and CEO
We do science.
Janssen Partnership

Development and Commercialization Partnership
for HBV and 3 New Targets

- Deal value up to $3.7bn
  - $250m up front
    - $175m cash + $75m equity at $23/share
  - $1.6bn in potential milestone payments for HBV, including $50m after P2 initiation
  - $1.9bn in potential milestone payments for the 3 new targets
    - Targets will be novel: not from our pipeline
    - Hepatocytes and non-hepatocytes possible
  - Tiered royalties to mid teens

Validation

The right partner

Capital: transformational opportunities

Investor and Analyst R&D Day 2018
TRiM™ Validation

- Amgen deal 2 years ago for Lp(a) and an undisclosed CV target
  - Progressing well: P1 milestone payment triggered for AMG 890
- Best in class speed
  - We will go from 0 to 5 clinical programs in 1 year
- Good and consistent activity with ARO-HBV and ARO-AAT in the clinic
- Good tolerability with ARO-HBV and ARO-AAT; more than 100 human subjects treated

Janssen provides additional validation with a 4 target deal: one of the largest non-acquisition potential deal values in biotech history
ARO-AAT

**Single Dose Cohorts**

- 35 mg
- 100 mg
- 200 mg
- 300 mg

**Decline in HBsAg (Log10)**

- 100mg q4w x 3 (C2b)
- 200mg q4w x 3 (C3b)
- 300mg q4w x 3 (C4b)
- 400mg q4w x 3 (C5b)
- 300mg q4w x 3 E+ nuc naive (C6)
- 300mg q4w x 3 E+ nuc exp (C9)
We view Janssen as an ideal partner for HBV

- Demonstrated clear commitment to HBV: most committed in pharma?
- Substantial resources with global reach
- Well positioned to take on the biology risk associated with addressing chronic HBV
  - Large, well-funded virology group
  - Multiple agents/mechanisms in-house
- Experience in complex global trials
  - Many cohorts will be required: HBV genotypes, different therapy combinations, different dosing schedules
- Well positioned for global launch
Capital Infusion: Transformational

Balance sheet and access to additional capital transforms our business

• Cash at last 10Q + Amgen payment: ~$90m
• $250m at close + $50m after ARO-HBV Phase 2 initiated = $300m of near-term capital
• Together $390m: represents 6-8 years of operations at current burn

• Will our burn increase over time? Yes, but:
  • ~$4bn of additional potential milestone payments between Janssen and Amgen

Enables us to create value as Pharmaceutical company rather than small biotech company
Arrowhead can now create value by retaining most of its pipeline and commercializing its drugs

Effectively traded clinical and commercial control of HBV and 3 novel targets (while retaining substantial upside exposure) for the ability to commercialize our own drugs

- Plans for ARO-AAT to initiate a Phase 2/3 study in Q1 2019
  - Pre-IND meeting with the FDA this month
  - Expectations for biopsies pre- and post-treatment
    - Decrease in monomer, polymer, and globules
    - Possible decrease in fibrosis
- 4 additional programs (now) targeting 3 different cell types
## Pipeline

<table>
<thead>
<tr>
<th>Competitive Position</th>
<th>Drug</th>
<th>Disease</th>
<th>Pre-clinical</th>
<th>Pre-IND</th>
<th>Phase 1</th>
<th>Phase 2</th>
<th>Phase 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>First RNAi</td>
<td>ARO-AAT</td>
<td>Alpha-1 Liver Disease</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>First RNAi</td>
<td>ARO-APOC3</td>
<td>Hypertriglyceridemia</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>First RNAi</td>
<td>ARO-ANG3</td>
<td>Dyslipidemia</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>First RNAi</td>
<td>ARO-ENaC</td>
<td>Cystic Fibrosis</td>
<td>Blue</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>First RNAi</td>
<td>ARO-HIF2</td>
<td>Renal Cell Carcinoma</td>
<td>Blue</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Leading RNAi</td>
<td>ARO-HBV</td>
<td>Hepatitis B</td>
<td>Green</td>
<td></td>
<td></td>
<td></td>
<td>Partnered with Janssen</td>
</tr>
<tr>
<td>First RNAi</td>
<td>AMG 890</td>
<td>Cardiovascular Disease</td>
<td>Green</td>
<td></td>
<td></td>
<td></td>
<td>Partnered with Amgen</td>
</tr>
<tr>
<td>Undisclosed Target</td>
<td>ARO-AMG1</td>
<td>Cardiovascular Disease</td>
<td>Green</td>
<td></td>
<td></td>
<td></td>
<td>Partnered with Amgen</td>
</tr>
</tbody>
</table>

**Drug Disease Pre-clinical Pre-IND Phase 1 Phase 2 Phase 3**

- Liver
- Lung
- Tumor

Investor and Analyst R&D Day 2018
Apolipoprotein C-III
Ira Goldberg, M.D.
Bronfman Professor of Medicine
Chief of the Division of Endocrinology, Diabetes and Metabolism
New York University Langone School of Medicine
Describe the causes of severe hypertriglyceridemia

Explain the evidence linking hypertriglyceridemia with acute and chronic disease
Clinical Signs of Severe Hypertriglycerideridemia

Eruptive Xanthomas

Lipemia Retinalis
How common and what are the risk factors for hyperTG pancreatitis

- Review of Kaiser Permanente, S. California
- Triglyceride over 1000 mg/dL (11 mMol)
- 5,550 patients/2.3x10^6 total. ~0.2%
- 301 (5.4%) with pancreatitis during the 12 month follow up
- 42.1% with diagnosis of unspecified hyperlipidemia (so most not with hyperTG)
- Pancreatitis group average TG 2,148 mg/dL
- Co-morbidities included younger age, alcohol, prior history, hypertension, renal disease.

Why does hyperchylomicronemia cause pancreatitis?

I don’t know!
Triglyceride (TG) and Lipoprotein Lipase (LpL)
TG from liver and gut use LpL

Chylomicron Transport

Endogenous Pathway
High Concentrations Of VLDL Block Chylomicron Lipolysis


Investor and Analyst R&D Day 2018
Increased TG as a function of genetics

What regulates lipolysis?

**Activators**
- ApoC-II (activator)
- GPIHBP1 (endothelial cell binding site)
- Lipase maturation factor (LMF, intracellular production)
- ApoA-V (increases binding to endothelial cells)

**Inhibitors**
- ApoC-III
- Angiopoietin-like proteins 3,4,8
A Null Mutation in Human \textit{APOC3} Confers a Favorable Plasma Lipid Profile and Apparent Cardioprotection

Toni I. Pollin,\textsuperscript{1} Coleen M. Damcott,\textsuperscript{1} Haiqing Shen,\textsuperscript{1} Sandra H. Ott,\textsuperscript{1} John Shelton,\textsuperscript{1} Richard B. Horenstein,\textsuperscript{1} Wendy Post,\textsuperscript{2} John C. McLenithan,\textsuperscript{1,3} Lawrence F. Bielak,\textsuperscript{4} Patricia A. Peyser,\textsuperscript{4} Braxton D. Mitchell,\textsuperscript{1} Michael Miller,\textsuperscript{1} Jeffrey R. O’Connell,\textsuperscript{1} Alan R. Shuldiner\textsuperscript{1,3}

Apolipoprotein C-III (apoC-III) inhibits triglyceride hydrolysis and has been implicated in coronary artery disease. Through a genome-wide association study, we have found that about 5\% of the Lancaster Amish are heterozygous carriers of a null mutation (R19X) in the gene encoding apoC-III (\textit{APOC3}) and, as a result, express half the amount of apoC-III present in noncarriers. Mutation carriers compared with noncarriers had lower fasting and postprandial serum triglycerides, higher levels of HDL-cholesterol and lower levels of LDL-cholesterol. Subclinical atherosclerosis, as measured by coronary artery calcification, was less common in carriers than noncarriers, which suggests that lifelong deficiency of apoC-III has a cardioprotective effect.
ApoC-3 ASO Reduced Triglycerides In LPL Deficiency
If apoC-III is an inhibitor of lipoprotein lipase, how does it lower TG in LpL deficiency?
Antisense Oligonucleotide (ASO)
Reduced TG but Did Not Increase HDL

Total Cholesterol

Most hypertriglyceridemia is not a pancreatitis risk

Does it cause heart disease?

Trials on-going
Comparison of ACCORD subgroup results with those from prior fibrate studies

<table>
<thead>
<tr>
<th>Trial (Drug)</th>
<th>Primary Endpoint: Entire Cohort (P-value)</th>
<th>Lipid Subgroup Criterion</th>
<th>Primary Endpoint: Subgroup</th>
</tr>
</thead>
<tbody>
<tr>
<td>HHS (Gemfibrozil)</td>
<td>-34% (0.02)</td>
<td>TG &gt; 200 mg/dl LDL-C/HDL-C &gt; 5.0</td>
<td>-71% (0.005)</td>
</tr>
<tr>
<td>BIP (Bezafibrate)</td>
<td>-7.3% (0.24)</td>
<td>TG ≥ 200 mg/dl</td>
<td>-39.5% (0.02)</td>
</tr>
<tr>
<td>FIELD (Fenofibrate)</td>
<td>-11% (0.16)</td>
<td>TG ≥ 204 mg/dl HDL-C &lt; 42 mg/dl</td>
<td>-27% (0.005)</td>
</tr>
<tr>
<td>ACCORD (Fenofibrate)</td>
<td>-8% (0.32)</td>
<td>TG ≥ 204 mg/dl HDL-C ≤ 34 mg/dl</td>
<td>-31%</td>
</tr>
</tbody>
</table>
• Icosapent ethyl (Vascepa) omega 3 fatty acid
• Four grams, >8,179 subjects at high risk
• Statin treatment on top of statin, LDL average 75
• Triglyceride >150 mg/dL, 150-499 mg/dL (average 216)
• PRESS RELEASE September 12, 2018, full data at AHA in November
• ~23% reduction in MACE
Why did this work?

- In higher risk subjects, higher dose, all subjects with increased triglycerides
- Reduced circulating triglyceride levels
- Altered the composition of lipolysis products, which may be anti-inflammatory
- Affected platelet function
- Altered intracellular signaling pathways – omega 3 changes in intracellular lipids
- Something special about this formulation
- WE DO NOT KNOW! AND REDUCED TG LEVELS OR REDUCED APOC-III COULD HAVE SIMILAR BENEFITS
Take Home Message

- Rare recessive genetic diseases lead to severe hypertriglyceridemia and pancreatitis.
- But this can occur in patients with a single mutations and a second insult: estrogen, alcohol, diabetes.
- Triglyceride and HDL levels are usually inversely correlated.
- Data on treatment of triglyceride to reduce CVD is inconclusive.
- Newer drugs (inhibitors of ApoC-III and Angplt3) will hopefully prevent hypertriglyceridemic pancreatitis and might also reduce CVD
ARO-APOC3
Bruce Given, M.D.
COO and Head of R&D
Some introductory thoughts
Public CV RNAi Programs Shows Growing Interest

<table>
<thead>
<tr>
<th>CV RNAi Programs</th>
<th>Company</th>
</tr>
</thead>
<tbody>
<tr>
<td>AngPTL3</td>
<td>Arrowhead</td>
</tr>
<tr>
<td>APOC3</td>
<td>Arrowhead</td>
</tr>
<tr>
<td>Cardiac amyloidosis</td>
<td>Alnylam</td>
</tr>
<tr>
<td>Lp(a)</td>
<td>Amgen *</td>
</tr>
<tr>
<td>PCSK9</td>
<td>Medicines Company ^</td>
</tr>
<tr>
<td>Undisclosed</td>
<td>Amgen *</td>
</tr>
</tbody>
</table>

* Licensed from Arrowhead
^ Licensed from Alnylam
Clinical Indications: Moderate to Severe Hypertriglyceridemia

Various etiologies, may be polygenic

Hegele et al., 2014
Triglyceride Levels Correlate with Frequency of Pancreatitis Attacks

$r_s=0.55$
$p<0.0001$
Plasma triglyceride levels are an independent risk factor for cardiovascular disease (Rosenson, ACC, 2014)

- Genetic studies support causal relationship
- Independent of LDL-C or HDL-C
## APOC3, ANGPTL3 Genetic Validation and Clinical Data

Mean or Median changes in lipid parameters after therapy and in heterozygotes and homozygotes for APOC3 and ANGPTL3 LOF mutations versus non-carriers

<table>
<thead>
<tr>
<th>Metric (serum level)</th>
<th>APOC3 deficient heterozygote</th>
<th>APOC3 deficient homozygote</th>
<th>APOC3 ASO inhibition</th>
<th>ANGPTL3 deficient heterozygote</th>
<th>ANGPTL3 deficient homozygote</th>
<th>ANGPTL3 ASO inhibition</th>
<th>ANGPTL3 Mab Inhibition</th>
</tr>
</thead>
<tbody>
<tr>
<td>ApoC-III</td>
<td>-46%</td>
<td>-88.9%</td>
<td>-77.5%</td>
<td>NA</td>
<td>NA</td>
<td>-58.8%</td>
<td>NA</td>
</tr>
<tr>
<td>ANGPTL3</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>-40% to -67%</td>
<td>undetectable</td>
<td>-84.5%</td>
<td>NA</td>
</tr>
<tr>
<td>Triglycerides</td>
<td>-39%</td>
<td>-59.6%</td>
<td>-43.8%</td>
<td>-21.1%</td>
<td>-71.2%</td>
<td>-50.4%</td>
<td>-76% i.v. (median)</td>
</tr>
<tr>
<td>LDL-C</td>
<td>-16%</td>
<td>Similar to non-carrier</td>
<td>-3.9%</td>
<td>-8.6%</td>
<td>-67.2%</td>
<td>-32.9%</td>
<td>-25%</td>
</tr>
<tr>
<td>HDL-C</td>
<td>+22%</td>
<td>+26.9%</td>
<td>+8.0%</td>
<td>-16.8%</td>
<td>-39.0%</td>
<td>-26.9%</td>
<td>-25%</td>
</tr>
<tr>
<td>CAD risk</td>
<td>-40%</td>
<td>Not reported</td>
<td>NA</td>
<td>-41%1</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Adverse Phenotype/AEs</td>
<td>None described</td>
<td>None described</td>
<td>Thrombocytopenia, ISRs, renal</td>
<td>None described</td>
<td>None described</td>
<td>None described</td>
<td>Elevated ALT (11% in active v 0% PBO)</td>
</tr>
</tbody>
</table>

1. Triglyceride working group, NEJM 2014
3. Graham et al., Circulation Research 2013. [Phase 1 MAD study, 400 mg dosed D1, D3, D5, D8, D15 and D22 with non-GalNac targeted ASO. Median % change 1-week after last dose in NHV population compared to baseline]
4. Minicocci et al., J of Lipid Research 2013
5. Dewey et al, NEJM 2017
6. Graham et al., NEJM 2017 [Six weekly 60 mg doses using GalNac conjugate ASO in NHV population, mean values 1 week after last dose versus baseline]
ARO-APOC3
Clinical Indications Related to High Triglycerides

Two primary indications to lower TGs with pharmacotherapy

1. Reduce pancreatitis risk (TGs > ~900 mg/dL)
   - Goal is to get well below 500 mg/dL to prevent pancreatitis associated with 2-3X rise post ETOH/fatty meal
   - Drugs used in conjunction with exercise, strict diet (< 20 grams of fat per day)

2. Reduce residual CVD risk following maximized LDL lowering
ApoC-III: What is it and Why is it Important?

- Apolipoprotein C3 (apoC-III) is a component of triglyceride rich lipoproteins (TRLs) including VLDL and chylomicrons and is a key regulator of triglyceride metabolism.
- apoC-III is primarily synthesized in hepatocytes (80%).
- apoC-III regulates triglyceride (TG) levels through several mechanisms:
  1. Inhibits hydrolysis of TGs by lipoprotein lipase (LPL).
  2. Attenuates hepatic uptake of triglyceride containing remnant lipoproteins.
Familial Chylomicronemia Syndrome (FCS)

- FCS: Severely elevated triglycerides (often over 2,000 mg/dL)
  - Loss-of-function in gene(s) responsible for LPL dependent triglyceride clearance (LPL, APOC2, APOA5, LMF1)
  - Multiple systemic manifestations
    - Recurrent abdominal pain
    - Acute pancreatitis (admission, narcotics, 10% mortality)
    - Neurocognitive problems
    - Type 2 diabetes mellitus
    - Eruptive xanthomas
- Estimated 3,000-5,000 patients worldwide
- No effective available therapy
  - Available drugs (fibrates, fish oils, niacin) ineffective as they work through LPL dependent pathway
  - Currently managed by severe dietary restrictions (< 20 grams of daily fat)
    - Adherence difficult, doesn't normalize triglycerides, only reduces pancreatitis risk
Familial Partial Lipodystrophy (FPL)

- FPL: mutations in genes responsible for efficient lipid storage in adipose tissue (e.g. LNMA gene, responsible for normal adipocyte development)
  - Multiple systemic manifestations
    - Very high triglycerides (>1000 mg/dL)
    - Pancreatitis
    - Insulin resistance
    - Hepatic steatosis
    - CVD
  
- Estimated 3,000-5,000 patients worldwide

- Very limited effective available therapy
  - Manage with low fat, high carbohydrate diet
Clinical Indications for APOC3: Tiered by Size and Regulatory Complexity

Rare diseases
6-10K patients
Worldwide (FCS, FPL)

Polygenic causes
moderate to severe
elevated TGs

Mild-moderate elevated TGs
Secondary CVD Prevention
RNAi for ApoC-III Brings Special Challenges

• Gene is small and has limited homology from rodents to humans/NHPs
  ✓ Solution – Human ApoC-III transgenic mouse for screening

• Lipid profiles in cynos are more like vegans than humans on a western diet
  ✓ Solution – High fructose fed rhesus study

• Proportion of ApoC-III coming from intestines appears much higher in NHPs than humans yielding confusing results from plasma ApoC-III measurements in cynos
  ✓ Solution – liver biopsy measurements in cynos (AHA abstract)
Single-dose Study in ApoC-III Transgenic Mice

- Deep KD after a single dose
- Max KD sustained for 3 weeks
- Expected effects on lipid profile

All dosed on study day 1 at 2 mpk
Data normalized to pre-dose and D5W control
ARO-APOC3 in Dyslipidemic Rhesus Monkeys

4 mg/kg ARO-APOC3 on Day 1 and 29

**Serum APOC3**

- Efficacy correlates to serum ApoC-III levels and severity of dyslipidemia

- Normalized APOC3 levels over weeks for Control and 4 mg/kg ARO-APOC3 groups.

- Normalized TG, TC, LDL-C, and HDL-C levels over weeks for Control and ARO-APOC3 groups.

Investor and Analyst R&D Day 2018
Plan for ApoC3

• AHA abstract Nov 12, 2018

• CTA planned for late in the year

• Plan for the protocol is to do single dose safety and PK in NHVs

• Multiple dose ranging in patients with elevated triglycerides

• Orphan indications would be FCS, FPL and polygenic elevated TGs with pancreatitis
Angiopoietin Like Protein 3
Ira Goldberg, M.D.
Bronfman Professor of Medicine
Chief of the Division of Endocrinology, Diabetes and Metabolism
New York University Langone School of Medicine
Two discoveries lead to the identification of novel regulators of plasma lipids

Angplt3 deficient mice

Hypobetalipoproteinemic patients
A new piece in the diabetes puzzle

Luciano Rossetti & Ira J. Goldberg


“Positional cloning has led to the identification of a liver-derived protein, angiopoietin-like protein 3, that is largely responsible for diabetic dyslipidemia in an animal model of type 2 diabetes”
Novel Regulators of Lipoprotein Lipase Activity

Dimeric LPL (active)  folded monomer (active, unstable)

Rapid equilibrium

Angptl-4

Partly unfolded monomer (inactive, stable)

Angiopoietin-like proteins 3, 4, 8

Angplt4 is highly regulated by PPAR transcription factors

Changes in its expression lead to altered LpL activity in adipose (not associated with changes in LpL mRNA or protein)

Angplt4 deficiency or inhibition leads to gut inflammation
65 year old woman

As a child was found to have difficulty eating foods with high fat and noted to have cholesterol levels below 50, most of which was HDL

Very low levels of fat soluble vitamins (A, D, E, K) and begun on supplements

Increased LFTs and NAFLD

Now with bilateral lower extremity numbness and unable to detect pin prick below the ankles.
Effects Of MTP And ApoB Inhibition

↓TG secretion results in ↑hepatic fat

Liver Cell

Intestinal Epithelial Cell

Apo B100 Degraded

Cytoplasm

ER

Lumen

Apo B48 Degraded

Cytoplasm

ER

Lumen

Investor and Analyst R&D Day 2018
ONE CAUSE OF HYPOBETALIPOPROTEINEMIA IS NOT ASSOCIATED WITH NAFLD AND MIGHT LEAD TO NEW TREATMENTS OF HYPERLIPIDEMIA
Exome Sequencing, ANGPTL3 Mutations, and Familial Combined Hypolipidemia

Kiran Musunuru, M.D., Ph.D., M.P.H., James P. Pirruccello, B.S., Ron Do, M.S., Gina M. Peloso, M.S., Candace Guiducci, B.S., Carrie Sougnez, B.S., Kiran V. Garimella, M.S., Sheila Fisher, M.L.A., Justin Abreu, M.S., Andrew J. Barry, B.S., Tim Fennell, B.S., Eric Banks, Ph.D., Lauren Ambrogio, B.S., Kristian Cibulskis, B.S., Andrew Kernytsky, Ph.D., Elena Gonzalez, B.S., Nicholas Rudzicz, M.S., James C. Engert, Ph.D., Mark A. DePristo, Ph.D., Mark J. Daly, Ph.D., Jonathan C. Cohen, Ph.D., Helen H. Hobbs, M.D., David Altshuler, M.D., Ph.D., Gustav Schonfeld, M.D., Stacey B. Gabriel, Ph.D., Pin Yue, Ph.D., and Sekar Kathiresan, M.D.

SUMMARY

We sequenced all protein-coding regions of the genome (the "exome") in two family members with combined hypolipidemia, marked by extremely low plasma levels of low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, and triglycerides. These two participants were compound heterozygotes for

Genetic and Pharmacologic Inactivation of **ANGPTL3** and Cardiovascular Disease.
PMID:28538136

Cardiovascular and Metabolic Effects of **ANGPTL3** Antisense Oligonucleotides.
PMID:28538111
In Mice – Angptl3 Modulate Fat Distribution
Kersten, Nat Rev. 13: 731, 2017
Fed – Angptl3 Reduces TG uptake in heart and BAT
Will Angptl3 Inhibition Decrease NAFLD and Improve Diabetes by Increasing Peripheral FA Oxidation?

Roles of Diacylglycerols and Ceramides in Hepatic Insulin Resistance
Max C. Petersen, Gerald I. Shulman
How does Angptl3 work?

Will it reduce TG levels in LpL deficiency?
Does it block liver production of lipoproteins (VLDL and LDL)?
Why?
How does it regulate cholesterol and LDL production?
ARO-ANG3
Bruce Given, M.D.
COO and Head of R&D
Clinical Indications for ARO-ANG3 Related to Dyslipidemias

Two primary indications to lower TGs with pharmacotherapy
• Polygenic patients with history of pancreatitis
• Secondary prevention for residual CVD risk following maximized LDL lowering

Familial hypercholesterolemia (FH) – non LDL receptor mechanism

One wild card indication
• NASH
### APOC3, ANGPTL3 Genetic Validation and Clinical Data

Mean or Median changes in lipid parameters after therapy and in heterozygotes and homozygotes for APOC3 and ANGPTL3 LOF mutations versus non-carriers

<table>
<thead>
<tr>
<th>Metric (serum level)</th>
<th>APOC3 deficient heterozygote¹</th>
<th>APOC3 deficient homozygote²</th>
<th>APOC3 ASO inhibition³</th>
<th>ANGPTL3 deficient heterozygote⁴</th>
<th>ANGPTL3 deficient homozygote⁴</th>
<th>ANGPTL3 ASO inhibition⁴</th>
<th>ANGPTL3 Mab Inhibition⁷ 25 mg/kg IV</th>
</tr>
</thead>
<tbody>
<tr>
<td>ApoC-III</td>
<td>-46%</td>
<td>-88.9%</td>
<td>-77.5%</td>
<td>NA</td>
<td>NA</td>
<td>-58.8%</td>
<td>NA</td>
</tr>
<tr>
<td>ANGPTL3</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>-40% to -87%</td>
<td>undetectable</td>
<td>-84.5%</td>
<td>NA</td>
</tr>
<tr>
<td>Triglycerides</td>
<td>-39%</td>
<td>-59.6%</td>
<td>-43.8%</td>
<td>-21.1%</td>
<td>-71.2%</td>
<td>-50.4%</td>
<td>-76% i.v. (median)</td>
</tr>
<tr>
<td>LDL-C</td>
<td>-16%</td>
<td>Similar to non-carrier</td>
<td>-3.9%</td>
<td>-8.6%</td>
<td>-67.2%</td>
<td>-32.9%</td>
<td>-25%</td>
</tr>
<tr>
<td>HDL-C</td>
<td>+22%</td>
<td>+26.9%</td>
<td>+8.0%</td>
<td>-16.8%</td>
<td>-39.0%</td>
<td>-26.9%</td>
<td>-25%</td>
</tr>
<tr>
<td>CAD risk</td>
<td>-40%</td>
<td>Not reported</td>
<td>NA</td>
<td>-41%¹</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Adverse Phenotype/AEs</td>
<td>None described</td>
<td>None described</td>
<td>Thrombocytopenia, ISRs, renal</td>
<td>None described</td>
<td>None described</td>
<td>None described</td>
<td>Elevated ALT (11% in active v 0% PBO)</td>
</tr>
</tbody>
</table>

1. Triglyceride working group, NEJM 2014
3. Graham et al., Circulation Research 2013. [Phase 1 MAD study, 400 mg dosed D1, D3, D5, D8, D15 and D22 with non-GalNac targeted ASO. Median % change 1-week after last dose in NHV population compared to baseline]
4. Minicocci et al., J of Lipid Research 2013
5. Dewey et al, NEJM 2017
6. Graham et al., NEJM 2017 [Six weekly 60 mg doses using GalNac conjugate ASO in NHV population, mean values 1 week after last dose versus baseline]
ASOs Appear to Aid Steatosis While Mabs Do Not

- Monoclonal antibodies cannot target intrahepatocyte ANGPTL3, will not improve NAFLD which is typical in metabolic syndrome in contrast to KD approach.
ANGPTL3 KD with ASOs Improve Insulin Resistance

WT mice with diet induced obesity treated with weekly 50 mg/kg (non-GalNac) anti-ANGPTL3 ASO x 6 week

No adverse changes in liver mass, transaminases or liver histopathology
Developing ARO-ANG3 Brings Less Challenges

- Good homology between mouse, cyno and human genes
- Can use standard mouse models of dyslipidemias
- Very little, if any, production outside of the liver
**ANGPTL3 Triggers – Wild Type Mice and Cynos**

- 80% KD with good duration at 0.5 mpk dose in mouse study
- Single dose at 3mpk provided 80% KD in NHP
Mouse disease models for ANGPTL3

- LDLr $^{-/-}$ mice, western diet (example shown today)
- Diet-induced obese (DIO) mice, 60% fat diet
- Leptin receptor defective db/db mice
ANGPTL3 Protein Knockdown in LDLr⁻/⁻ Mice

- Western Diet D5W
- Western Diet 3mpk ARO-ANG3
- Western Diet 3mpk control trigger
- Normal Chow IG
- Normal Chow 3mpk ARO-ANG3

Max 94% KD
Max 98% KD

Normalized ANGPTL3 vs Days

Investor and Analyst R&D Day 2018
ARO-ANG3 Reduces Triglycerides in LDLr⁻/⁻ mice

- Western Diet D5W
- Western Diet 3 mpk ARO-ANG3
- Western Diet 3 mpk control trigger
- Normal Chow D5W
- Normal Chow 3 mpk ARO-ANG3
ARO-ANG3 Reduces LDL-C in LDLr⁻/⁻ mice

- Deep ANGPTL3 KD in both Western diet or chow-fed mice
- Significant decreases in lipid parameters
- Western diet-fed mice had similar or better % decrease in lipid parameters but absolute values still higher than chow-fed mice

**Western Diet D5W**
- **Western Diet 3 mpk ARO-ANG3**
- **Western Diet 3 mpk control trigger**
- **Normal Chow D5W**
- **Normal Chow 3 mpk ARO-ANG3**

**LDL-C**

**Normalized LDL**
Clinical Indications: Tiered by Size and Regulatory Complexity

- Rare diseases
  - ~6-10K patients
  - WW (e.g. FPL, HoFH)
- Polygenic causes moderate to severe elevated TGs
- Mild-moderate elevated TGs
- Secondary CVD Prevention
- NAFLD/NASH Reduction
Plan for ARO-ANG3

- AHA oral presentation November 12, 2018

- CTA submitted on October 12, 2018
  - Single and multiple doses in NHVs with high enough TGs for dynamic range

- Multiple doses in special populations
  - NAFLD to assess effect on liver fat
  - Treated hypercholesterolemics to assess ability to knock down further
  - Familial hypercholesterolemia
  - Polygenic hypertriglyceridemia (>500 mg/dl)

- **Orphan indication would be familial hypercholesterolemia**

- Mass populations would be secondary prevention (independent of LDL but with added LDL benefit) and/or NASH
Targeted RNAi Molecule (TRiM™) Platform
Zhen Li, Ph.D.
Senior Vice President, Chemistry and Non-Clinical Development
TRiM™ - Potency, Activity, Durability and Safety

• Based on insights at molecular level of critical factors in each step of RNAi:
  • RISC loading, mRNA cleavage, trigger metabolism, off target interactions
• Enables us to uncover potent and efficacious sequences
  • Identify RNA triggers based on intrinsic characteristics
    • See what others have not
• Allows us to stabilize/improve sequences when needed
  • Achieve long duration and increase activity
• Enables us to have a wide therapeutic index on our compounds
  • Can afford to be very stringent in sequence selection
    • Through bioinformatic analysis, exclude sequences with potential off-target effects due to sequence homology and microRNA
    • Significant advantage for RNAi compared with small molecule therapeutics

Targeted RNAi Molecule
TRiM™ platform
Our Story Since Unveiling TRiM™ Platform in 2017

- Three candidates entered the clinic, and currently in phase 1/2 clinical studies
  - ARO-AAT (entering phase 2)
  - ARO-HBV (phase 1/2)
  - AMG 890 (phase 1, partnered with Amgen)

- Two candidates at clinical submission stage
  - ARO-ANG3
    - Completed GLP toxicology study, filed CTA
  - ARO-APOC3
    - Completed exploratory toxicology studies, in GLP toxicology study now

- Our insight enables speed and high success rates in our development programs
  - All candidates (clinical and pre-clinical) are potent, efficacious and have been well tolerated
  - No candidates failed at GLP toxicology studies stage or exploratory tox stage (100% success rate to date)
ARO-AAT Clinical Data Shows Platform Promise

- **Open Label AAT Plasma Data:**
  Single Dose, Healthy Volunteers

- **Safety**
  - No SAEs
  - Most AEs reported as mild (one moderate gastroenteritis)
  - Mild injection site AEs occasionally reported
  - No clinically meaningful adverse changes in BUN, creatinine, ALT, AST or total bilirubin or pattern of adverse laboratory changes seen
ARO-HBV Carries the Same Message

HBsAg Reduction with ARO-HBV After 3 monthly Doses

- Safety
  - No SAEs reported
  - No subject dropouts
  - Mild injection site AEs occasionally reported (~11% of injections)
  - No pattern of adverse laboratory changes reported
TRiM™ for Extrahepatic Targets
TRiM™ Platform for Extrahepatic Delivery

Requires all components of TRiM™ working synergistically

- RNAi sequence selection and optimization
  - Paramount importance
  - Determines potency, specificity (off-target) and stability of the conjugate
TRiM™ Platform for Extrahepatic Delivery

Requires all components of TRiM™ working synergistically

- RNAi sequence selection and optimization
  - Paramount importance
  - Determines potency, specificity (off-target) and stability of the conjugate

- Ligand/receptor pairs discovery and development
  - Critical for RNAi delivery
    - Enable tissue specific, cell specific delivery and maximum potency
    - Require deep expertise in medicinal chemistry and biology for ligand discovery and SAR

- PK enhancers
  - To maximize circulation time for ligand/receptor interaction

- Linker optimization - SAR here also can improve activity

**Potency, Activity, Durability and Safety**
ARO-HIF2
For the treatment of ccRCC (clear cell renal cell carcinoma)
Ligand/Receptor and PK Enhancers

A498 Tumor Model: Hif2a Expression

- Trigger alone - no delivery
- Clear ligand effect observed
- PK enhancer plays critical role

**Demonstrated Synergistic Effects of Ligand and PK Enhancer**
Increasing Potency and Enabling Subcutaneous Administration

• Subcutaneous vs IV ROA
• ARO-HIF2 demonstrates equal or better potency via subcutaneous administration compared with IV
• Demonstrates the power of TRiM™ platform

Achieved Efficient silencing of an Extrahepatic Target gene via Subcutaneous Administration
Wide Therapeutic Index and Good Durability

• **Safety**
  • Exploratory toxicity study in rats (non-GLP) with Gen4B-HIF2
    • 3 daily doses of 30 mpk each given over 5 weeks (total of 15 doses) by IV injection
    • Compared with dosing in TGI study – 5 mpk, twice a week for 2 weeks, followed by weekly doing of 5 mpk for 3 weeks (total of 7 doses of 5 mpk each)

  ![Diagram of A498 tumor Hif2 expression](image)

• **Durability**
  • About 10-day duration

  ![Graph of relative expression](image)

No significant findings or indications of toxicity observed
New Extrahepatic Tissue - Muscle
Deep Knockdown across Multiple Muscle Types

- Single dose of 5 mpk produced close to 80% target protein reduction and efficient mRNA knockdown
Summary and Next Steps

- **TRiM™ platform** demonstrates versatility for both hepatic and extrahepatic targets
  - Potency, efficacy, durability and safety
  - Speed and high success rate
- **Hepatocyte targets**
  - Expertise in RNAi chemistry and biology
  - We have yet to encounter a hepatocyte gene that we could not knock down effectively and with wide therapeutic index
- **Extrahepatic targets**
  - Requires all TRiM™ platform modules to be fully optimized
  - Expertise in uncovering ligand/receptor pairs
  - Expertise in ligand designs to enable maximal uptake through endocytosis
  - Successful extrahepatic, systemic delivery of RNAi triggers via IV and subcutaneous administrations in ccRCC

*Every tissue is a new frontier in RNAi – we can potentially target any gene in any tissue using the power of RNA interference*
ARO-ENaC Gen 1
Erik Bush, Ph.D.
Senior Director, Extra-Hepatic Targeting
• Increased ENaC channel activity is seen with all cystic fibrosis genotypes
• Loss-of-function alleles of ENaC subunits increase mucociliary clearance, resulting in milder CF phenotypes
• Gain-of-function alleles of ENaC subunits worsen CF phenotypes
• ENaC inhibitors promise genotype-agnostic therapeutic approach for all CF patients, including those with Class I mutations that produce no CFTR protein
• Common mechanism in other muco-obstructive lung diseases like COPD, bronchiectasis & asthma
Inhaled Small Molecule ENaC Inhibitors Limited by On-Target Renal Toxicity and Short Duration of Action in Lung

Parion, Gilead, Vertex, Amgen, AZ, Novartis, BI

- Inhaled small molecule inhibitors transiently improve lung clearance, but are rapidly absorbed
- Systemic exposure results in renal ENaC inhibition and hyperkalemia

"The rational design of new ENaC blockers must include not only the provision of a sustained increase in mucociliary clearance, but also the avoidance of clinically significant renal exposure..."
• Optimized RNAi trigger sequence vs. $\alpha$ENaC mRNA

• Integrin $\alpha\nu\beta6$ ligands facilitate uptake and endocytosis of triggers by pulmonary epithelium

ARO-ENaC

$\alpha$ENaC trigger

epithelial targeting ligand

EpL = integrin $\alpha\nu\beta6$ ligand
EpL-trigger Conjugates Internalized by Human Bronchial Epithelial Cells and Reduce αENaC Expression and Activity

Fully differentiated HBE cells in air-liquid interface culture

αENaC mRNA expression

ENaC current

Airway surface liquid volume

Investor and Analyst R&D Day 2018
EpL-trigger Conjugates Internalized by Rat Bronchiolar Epithelial Cells in vivo Following Oropharyngeal Delivery

Red: trigger
Green: actin
Blue: nucleus
Inhalation of Aerosolized ARO-ENaC Gen 1 Selectively Silences αENaC mRNA Expression in the Rat Lung

- No changes in renal αENaC mRNA expression or serum potassium levels
- Well-tolerated, with no significant findings in clinical chemistry, hematology or histopathology
ARO-ENaC Gen 1 Durably Silences Lung αENaC mRNA Expression

Durable mRNA silencing supports every other week (or less frequent) dose regimens

Investor and Analyst R&D Day 2018
Sheep Airway Mucociliary Clearance Study

**Mucociliary clearance (MCC) measurements:** pre-dose baseline and Day 17
- Inhalation of aerosolized $^{99m}$Tc-labeled sulfur colloid
- Clearance measured via gamma imaging (5 min intervals over two hours)

**Groups 1-3** (n=3 each): aerosolized ARO-ENaC Gen 1 on Days 1-3
- 0.07, 0.35 or 0.7 mg/kg deposited dose

**Group 4** (n=2): aerosolized amiloride (3 mL 3 mM) on Day 17
- Administered immediately prior to MCC scan (1-2 hour effect in lung)
ARO-ENaC Gen 1 Increases Mucociliary Clearance in Sheep Two Weeks after Inhaled Dosing
ARO-ENaC Gen 1 Increases Mucociliary Clearance in Sheep two Weeks after Inhaled Dosing

Day 17 mucociliary clearance

ARO-ENaC Gen 1 was well-tolerated at all doses
Conclusions and Next Steps

• NACFC poster presentation October 18, 2018

• Inhaled ARO-ENaC Gen 1 conjugates produce selective, durable, renal-sparing silencing of pulmonary αENaC expression

• Improved mucociliary clearance is observed in sheep two weeks after inhalation of aerosolized Gen 1 conjugate

• Work on next-generation ARO-ENaC is focused on further increasing potency to produce in vivo clearance increases similar to short-acting small molecule ENaC inhibitors

• The platform may be adapted to additional therapeutic targets in the pulmonary epithelium, particularly those that are currently inaccessible to traditional small molecule or antibody approaches
ARO-HIF2
So Wong, Ph.D.
Director, Oncology
Clear Cell Renal Cell Carcinoma (ccRCC)

- Kidney cancer is one of the 10 most common cancers
  - 64,000 new cases in 2017
- 70-80% of kidney cancer are ccRCC
  - Characteristic clear cytoplasm due to lipid and glycogen accumulation
- In most ccRCC, the Von Hippel-Lindau (VHL) tumor suppressor gene is inactivated
  - pVHL regulates the degradation of hypoxia inducible factors (HIFs)
  - VHL inactivation leads to accumulation of HIFs
- HIFs transcriptionally activates numerous genes involved in cellular processes including glycolysis, angiogenesis, and metastasis of cancer cells
- Various studies link HiF2α overexpression as a tumorigenic driver of ccRCC
• ARO-HIF2 is our first systemic extrahepatic program

• TRiM™ molecule that uses a receptor that is over-expressed in many cancers
  • Tumor tissue microarrays confirmed receptor expression in ccRCC

• RNAi trigger specifically targets HIF2α mRNA
  • Limited restrictive expression in normal tissues
  • Over-expression in ccRCC
  • Minimal off-target risks
  • Chemically modified to enhance potency and prevent immune activation

• Exploratory safety studies predict a wide therapeutic margin
MOA: ARO-HIF2 vs Small Molecule HIF2α Inhibitor

- HIF2α/HIF1B dimer regulates transcription pathways that promote tumor growth and metastasis

- Small molecule HIF2α inhibitor (Peloton) prevents binding of HIF2α to HIF-1B

- ARO-HIF2 employs RNAi to degrade HIF2α mRNA and prevent production of HIF2α protein and down-regulate target genes

Riazalhosseini and Lathrop, Nature Reviews Nephrology, 2016
ARO-HIF2 in Tumor Growth Inhibition Study

A498 orthotopic kidney xenograft mouse model

- A498 is an established ccRCC cancer cell line
- Tumor growth by SEAP expression
  - Stably expresses SEAP (secreted embryonic alkaline phosphatase)
  - Good correlation between SEAP levels and tumor volumes
- Sensitive serum biomarker to monitor tumor growth

Investor and Analyst R&D Day 2018
Tumor delivery is ligand dependent

No ligand

With Ligand

- Efficient delivery to all tumor cells
- No delivery without ligand

2 mg/kg Cy3-labeled ARO-HIF
4 h after injection

Red = ARO-HIF2
Blue = nuclei
Green = actin fiber (cell membrane)

A498 ccRCC orthotopic tumor mouse model
ARO-HIF2 Inhibits Tumor Growth

**A498-SEAP orthotopic xenograft mouse model**

- Deep HIF2α mRNA knockdown with lower dose levels and frequency compared to earlier generations
- Inhibition of tumor growth by SEAP expression and tumor mass

![Graph showing relative HIF2α expression and tumor weight over study days]
ARO-HIF2 Induces Tumor Degeneration

- ARO-HIF2 treated group showed widespread tumor damage
- Areas of apoptosis and necrosis
- Loss of clear cell characteristic
Evaluation in Patient Derived Xenograft Models

• Fragments or cells from a patient’s tumor implanted into immunodeficient mice

• Advantages over established cancer cell lines
  • Maintains the genetic abnormality found in the patient
  • Reduced transformation of tumor cells
  • May be more predictive of patient response
Survival Study: Patient Derived Xenograft (PDX) Mouse Model with Prior Generation Compound

- Dosing began 4 days after tumor implant, 3 daily doses/week (15 mpk/dose)
- Monitor body weight weekly and health check daily
- Palpate tumor weekly to estimate growth rate
- End-point is overall survival
Improved Overall Survival in PDX Mouse Model

Kaplan-Meier survival analysis

- **Control (n = 11)**
- **Treatment (n = 12)**

Tumor Histopathology with Gen2
- Frequent tumor necrosis/degeneration
- Less invasiveness at tumor/kidney interface

HiF2α mRNA KD

<table>
<thead>
<tr>
<th></th>
<th>D5W n=10</th>
<th>TRiM n=12</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean</td>
<td>1.000</td>
<td>0.496</td>
</tr>
<tr>
<td>Relative hHuHIF2α Expression</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Investor and Analyst R&D Day 2018
ARO-HIF2 Reduced PDX Tumor Invasiveness

- Less invasiveness at tumor/kidney interface with clear demarcation line between tumor and kidney
- Silencing HIF2alpha may prevent metastasis development

A new survival study using the current lead candidate is on-going
Summary and Plan for ARO-HIF2

Summary
• Efficient ligand dependent tumor delivery of ARO-HIF2 demonstrated
• Deep HIF2α mRNA knockdown in tumor
• Inhibition of tumor growth and improved overall survival in tumor models
• Rat exploratory toxicity studies predict a wide safety margin

Plan
• Late breaking poster at the EORTC/AACR/NCI symposium, Nov 13 - 16
• Development candidate nomination in coming months
• CTA planned for 2019
Concluding Remarks
Chris Anzalone, Ph.D.
President and CEO
2019 will be productive

- **Expect 2 new CTAs**
  - ARO-HIF2
  - ARO-ENaC

- **Expect to be in Phase 2 or later with 3 wholly-owned candidates**
  - ARO-AAT, ARO-ANG3, ARO-APOC3

- **Expect progress with partnered clinical candidates**
  - ARO-HBV, AMG 890

- **Wildcards**
  - New Janssen targets
  - Amgen undisclosed CV target
  - Muscle targeting
  - ARWR breakthroughs
Looking Beyond 2019

Innovation and speed will continue to define us

- We expect 2 - 3 new CTAs every year
- We expect to be able to target a new cell type every ~18 months
- We expect 10 TRiM™ enabled clinical programs by the end of 2020
- Just need to execute: look to the past year for our ability to execute
Q&A Session
Panelists